English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Open

Presents the pdf analysis as premium feature

PDF Analysis

Insights

Presents the summarisation as premium feature

Summarisation

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

The real‐world evidence on the profiles of patients suffering from atopic dermatitis ( AD ) in Japan is sparse. A retrospective claim database analysis was conducted to estimate the health‐care resource use ( HCRU ) and current  AD  treatment. Data from October 2013 to September 2016 were extracted from the  JMDC  (Tokyo, Japan) claims database.  HCRU  was assessed by a comparison of  AD  patients and matched non‐ AD  controls. A multivariate analysis was performed to estimate  HCRU  attributable to  AD .  AD  patients ( n  = 39 893) have more claims of certain diagnoses such as rhinitis, viral and fungal infections, sleep disorders and conjunctivitis as well as higher  HCRU  (outpatient visits, prescriptions of  AD ‐related and non‐ AD ‐related medications, phototherapy, laboratory tests) than matched non‐ AD  controls ( n  = 39 893). Treatment pattern analysis included treatment‐naive patients ( n  = 8478) and previously treated  AD  patients ( n  = 30 109). Approximately 20% of previously treated patients were on the continuous systemic treatment during 18‐month follow up. Systemic corticosteroids were the most frequently used systemic treatments. Oral cyclosporin was less frequently used in both groups, but for the longest duration. Almost half of previously treated patients with oral cyclosporin continued treatment for more than 3 months. In conclusion,  HCRU  was higher in  AD  patients than non‐ AD  controls, indicating a high burden of the disease imposed on  AD  patients. Continuous administration of systemic treatment, such as oral cyclosporin, systemic corticosteroids and phototherapy, observed in  AD  patients sheds light on the difficulties of managing  AD  in Japanese clinical practise.

Health‐care resource use and current treatment of adult atopic dermatitis patients in Japan: A retrospective claims database analysis